Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Serum S100--a Marker For Disease Monitoring In Metastatic Melanoma.

G. Henze, R. Dummer, H. Joller-Jemelka, R. Boeni, G. Burg
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
BACKGROUND S100 proteins are low-molecular-weight calcium-binding proteins and appear to play an important role in various cellular processes such as cell division and differentiation. In histopathology, S100 is widely accepted as the marker of choice for immunohistochemical identification of malignant melanoma. When S100 was detected in the serum of patients with malignant melanoma, it was suggested that serum S100 may be a useful marker for the stage of disease. OBJECTIVE The aim of this study was to examine serum S100 concentrations of patients with different stages of malignant melanoma and to determine the value of serum S100 in the follow-up of melanoma patients during treatment. METHODS Sera were obtained from 73 melanoma patients in different stages of the disease. The control group consisted of 130 healthy subjects. In 4 patients with metastatic melanoma, serum S100 was measured serially. Serum levels were measured by a commercially available immunoradiometric assay. RESULTS While only 1 out of 25 stage I/II patients and 3 of 14 patients with lymph node metastases (stage III, 21.4%) showed detectable serum S100 levels, 27 of 34 patients with disseminated disease (stage IV, 79.4%) had elevated serum S100. Interestingly, rising levels of serum S100 in the serial measurement indicated progression of the disease, and a complete decline reflected 2 patient remissions. CONCLUSION The data support the value of serum S100 as a clinical marker for progression of metastatic melanoma and serological monitoring during systemic therapies.

This paper is referenced by
S-100 Protein Serum Levels in Patients with Benign and Malignant Diseases: False-Positive Results Related to Liver and Renal Function
R. Molina (2002)
Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.
C. Garbe (2003)
Neue Strategien und Konzepte in Diagnostik und Nachsorge des malignen Melanoms
C. Voit (2003)
Biomarkers for Melanoma Diagnosis and the Technologies Used to Identify Them
T. Mori (2011)
Mutated MITF-E 87 R in Melanoma Enhances Tumor Progression via S 100 A 4
Alice Nordlinger (2018)
The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor‐receptor 1 in psoriasis
B. Kirby (2001)
Melanoma progression and serum l-dopa/l-tyrosine ratio: a comparison with S100B
K. Stoitchkov (2002)
Biomarkers in melanoma: staging, prognosis and detection of early metastases
J. Carlson (2003)
Successful topical immunotherapy of bowenoid papulosis with imiquimod
W. Petrow (2001)
A novel versatile animal-free 3D tool for rapid low-cost assessment of immunodiagnostic microneedles
S. Totti (2019)
S-100β Protein – Serum Levels in Children with Brain Neoplasms and its Potential as a Tumor Marker
A. Rajendra (2004)
Decreased expression of Fas (APO‐1/CD95) on lesional CD4+ T lymphocytes in cutaneous T cell lymphomas: correlations with blood data
O. Dereure (2001)
Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma
Åsa Bolander (2008)
Is increased serum S-100 protein concentration a marker of metastasis in malignant melanoma? A four-year experience report
M. Governa (2004)
S-100β-Protein im Serum als Tumormarker beim malignen Melanom Aktueller Kenntnisstand und klinische Erfahrungen
A. Jäckel (1999)
Protein profiles in sera of patients with malignant cutaneous melanoma.
L. Ferrari (2000)
Melanoma—Diagnosis, Subtypes and AJCC Stages
Anand Rotte (2016)
La proteína S100 como marcador tumoral en pacientes con melanoma. Estudio comparativo con ganglio centinela y la exploración FDG-PET
B. Ortíz (2003)
Prospective E valuation o f a F ollow-Up S chedule i n C utaneous Melanoma P atients: R ecommendations f or a n E ffective Follow-Up S trategy
C. Garbe (2003)
Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma—An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer
R. U. Wahl (2020)
Cutaneous melanoma: baseline and ongoing laboratory evaluation
C. Garbe (2005)
Prognostic Significance and Diagnostic Value of Protein S-100 and Tyrosinase in Patients With Malignant Melanoma
R. Andrés (2008)
Alopecia areata associated with regression of cutaneous melanoma
M. Yousefi (2006)
Tissue microarray based biomarker study in human cutaneous melanoma
Y. Cheng (2014)
Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients
C. Garbe (2003)
Characterization of the monoclonal antibody specific to human S100A6 protein
J. W. Kim (2002)
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes
Jia-Ren Lin (2018)
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Riikka Harpio (2004)
Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
E. D. Mårtenson (2001)
Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
B. Schlagenhauff (2000)
Luminometrische Bestimmung von Protein S100 bei malignem Melanom
S. Reichenauer (2006)
Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy
Athanasios Blanas (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar